Who founded Dualitas Therapeutics?

Dualitas Therapeutics was founded by Greg Lazar, Ph.D. in 2023.

Who are Dualitas Therapeutics's investors?

Dualitas Therapeutics's investors include Qiming Venture Partners, SV Health Investors, Versant Ventures, Alexandria, Dementia Discovery Fund, Qiming Healthcare, Qiming Venture Partners USA.

How much funding has Dualitas Therapeutics raised?

Dualitas Therapeutics has disclosed $32.6M raised across 1 round.

Where is Dualitas Therapeutics headquartered?

Dualitas Therapeutics is headquartered in South San Francisco, US.

Dualitas Therapeutics

South San Francisco, US · Founded 2023 · Delaware corporation · 21 employees on LinkedIn · 7 known investors

Find your way into Dualitas Therapeutics

Paths you didn't know you had: your email and LinkedIn already hold routes to the Dualitas Therapeutics team. We find them for you
2nd- and 3rd-degree connections: the friend-of-a-friend routes that take hours to manually find through your inbox or LinkedIn
Answers now, not in days: momentum is everything in a raise. Skip asking around whether someone knows someone

Days of research, done the moment you sign in, with every route ranked by how warm it is.

Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.

Biotech Deep Tech

Founders & leadership

Dualitas Therapeutics was founded in 2023 by Greg Lazar, Ph.D..

Greg Lazar, Ph.D.Co-Founder and Chief Scientific Officer

Forbes Huang Co-Founder, COO & CBOHe previously held senior roles at Gyroscope Therapeutics (acquired by Novartis), IVERIC bio (acquired by Astellas), and a Novo Holdings-backed startup (acquired by Insmed), as well as positions in investment banking at Morgan Stanley and private equity at H.I.G. Capital. He holds an MBA from Wharton and dual bachelor's degrees in Finance and Economics from NYU Stern.

Greg LazarCo-Founder and Chief Scientific Officer

Richard MurrayExecutive

Karim Dabbagh Chief Executive Officer, Board MemberKarim Dabbagh holds a Ph.D. in biochemistry from University College London and completed postdoctoral fellowships at UCSF and Stanford; he previously led the immunoregulation department at Pfizer, founded Modus BioMedicine for transplantation and autoimmune therapies, spent nine years at Roche in inflammation research roles, and served as CEO of Second Genome and Silver Creek Pharmaceuticals.

Board

Alicia LeveyBoard directorVenture Partner at Versant Ventures

Michael RossBoard directorSenior Partner at Dementia Discovery Fund

Neil WeirBoard directorVenture Partner at Dementia Discovery Fund

Mark McDade Board directorGeneral Partner at Qiming Healthcare

Nikola TrbovicBoard directorManaging Partner at Dementia Discovery Fund

Thomas HudsonBoard director

Investors · 7

Qiming Venture Partners✓ confirmed by Dualitas TherapeuticsBeijing

How we know: the company's own site · Not right? Tell us

SV Health Investors✓ confirmed by Dualitas TherapeuticsLondon · $1M – $20M

How we know: the company's own site · funding news · Not right? Tell us

Versant Ventures✓ confirmed by Dualitas TherapeuticsSan Francisco · $250K – $5M

How we know: the company's own site · funding news · Not right? Tell us

AlexandriareportedPasadena

How we know: funding news · Not right? Tell us

Dementia Discovery FundinferredLondonvia Neil Weir · board

How we know: board seat on SEC Form D · Not right? Tell us

Qiming HealthcareinferredBellevue

How we know: board seat on SEC Form D · Not right? Tell us

Qiming Venture Partners USAreportedCambridge

How we know: funding news · Not right? Tell us

Reported raises · per SEC filings

Form D private placements

$32.6M disclosed across 1 round · 2025

▶$32.6MraisedNov 2025 · 7 investors · Biotechnology

Rule 506(b)

Officers, directors & promoters on the filing

Thomas HudsonDirector
Forbes HuangExecutive Officer
Alicia LeveyDirector
Michael RossDirector
Greg LazarExecutive Officer
Neil WeirDirector
Mark McDadeDirector
Richard MurrayExecutive Officer, Director
Nikola TrbovicDirector

Offering amount: $66.6M
Amount sold: $32.6M
First sale: Jul 2025
Incorporated: Corporation, Delaware, 2023
Federal exemptions: 06b

Full filing on SEC EDGAR ↗

Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.

Related companies · 5

Immunitas TherapeuticsImmunitas discovers and develops therapeutic antibodies for cancer and autoimmune diseases, with its lead program targeting CD161 for solid tumors and hematological malignancies. The company is building on research from academic institutions including Dana Farber Cancer Institute and MIT.

Abilita TherapeuticsAbilita Therapeutics is a drug discovery company focused on membrane protein targets, using its EMP (Enabled Membrane Proteins) technology based on directed evolution to create stability- and expression-enhanced protein variants for discovering and optimizing drug candidates.

Fortis Life SciencesFortis Life Sciences develops and manufactures Bethyl-branded ELISA kits and related reagents, buffers, and antibodies for detecting target proteins in research and diagnostic applications. The kits cover human and veterinary targets and are made in the USA using the company's own antibodies.

Cabaletta BioCabaletta Bio is a clinical-stage biotechnology company developing engineered T cell therapies for patients with autoimmune diseases. Its CABA platform and lead CARTA program center on rese-cel, an investigational CD19-CAR T cell therapy being evaluated in trials across rheumatology, neurology, and dermatology.

AlloyAlloy provides drug discovery services and platform technologies across genetic medicines, TCR mimics, and cell therapies, supporting pharmaceutical partners in developing novel treatments.

Companies working in the same space as Dualitas Therapeutics.

Frequently asked questions

What does Dualitas Therapeutics do?: Dualitas Therapeutics develops bispecific antibody therapies that pair a proprietary proximity engager arm with an antibody against a therapeutic target, using its DualScreen discovery engine to identify synergistic target combinations. Its pipeline targets autoimmune, allergic, and other immune and inflammatory diseases, with lead candidate DTX-102 for rheumatoid arthritis in IND-enabling studies.
Who founded Dualitas Therapeutics?: Dualitas Therapeutics was founded by Greg Lazar, Ph.D. in 2023.
Who are Dualitas Therapeutics's investors?: Dualitas Therapeutics's investors include Qiming Venture Partners, SV Health Investors, Versant Ventures, Alexandria, Dementia Discovery Fund, Qiming Healthcare, Qiming Venture Partners USA.
How much funding has Dualitas Therapeutics raised?: Dualitas Therapeutics has disclosed $32.6M raised across 1 round.
Where is Dualitas Therapeutics headquartered?: Dualitas Therapeutics is headquartered in South San Francisco, US.